Table 1. Patient characteristics.

	Median/Category	Min-Max range/N (%)
Sex	Female	N = 8 (53%)
	Male	N = 7 (47%)
Age	35.15 year	25.47–49.36
MS duration since first symptoms	3.47 year	0.63–5.58
Time since last relapse	0.96 year	0.21–3.35
Number of relapses last 12 months	1.0	0.0–3.0
EDSS score*	2.0	0.5–4.0
Duration of IFN-β use	1.21 year	0.14–4.47
IFN-β type	Avonex®	N = 3 (20%)
	Betaferon®	N = 3 (20%)
	Rebif®	N = 9 (60%)
Race	Caucasian	N = 14 (93%)
	Hispanic	N = 1 (7%)

^*Expanded Disability Status Scale [34].